[Telmisartan in monotherapy of essential hypertension in young men--time of drug administration and 24-hours blood pressure and heart rate].
42 men, aged 19-35 years (mean 26.3), with mild or moderate essential hypertension (DBP 95-110 mmHg), were treated with telmisartan (40 mg or 80 mg ) once daily in the morning (6 and 7 a.m.) for at least 6 weeks and for next 6 weeks and after that administration time was changed to evening dose (6-7 p.m.) 24-hours ABPM (SpaceLabs) was performed in all patients on last day of each period. Obtained recordings were compared in different periods of time: 6.00 a.m. -10.59 p.m., 11.00 p.m-5.59 a.m., 2.00-5.59 a.m., 6.00-12.00 a.m, 3.00-7.00 p.m. The SBP values in all time intervals were comparable (differences statistically not significant). A statistically significant reduction of the DBP in the time interval 6:00-12:00 a.m. was found in patients treated with telmisartan in the morning. The heart rate of the patients who received telmisartan has not been affected by the treatment schedule and remained comparable.


CONCLUSIONS
1.) The time of the day administration does not affect the diurnal and night hypotensive efficacy of telmisartan. 2.) According to the results of this study, patients with the essential hypertension should receive telmisartan as monotherapy in the morning.
Niegowska
Joanna
J
Instytut Kardiologii, Warszawa-Anin, Warszawa.
Niegowska
Magdalena
M
Jasiński
Bogdan
B
D000328:Adult; D000959:Antihypertensive Agents / Q000494:pharmacology / Q000627:therapeutic use; D001562:Benzimidazoles / Q000008:administration & dosage* / Q000494:pharmacology; D001565:Benzoates / Q000008:administration & dosage* / Q000494:pharmacology; D001794:Blood Pressure / Q000187:drug effects*; D018660:Blood Pressure Monitoring, Ambulatory; D019454:Chronotherapy; D002940:Circadian Rhythm; D004334:Drug Administration Schedule; D006339:Heart Rate; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D016037:Single-Blind Method; D000077333:Telmisartan; D016896:Treatment Outcome
D000959:Antihypertensive Agents; D001562:Benzimidazoles; D001565:Benzoates; D000077333:Telmisartan